1 / 22

Osteopontin expression in salivary gland cancer

Osteopontin expression in salivary gland cancer. Kristine Bjørndal, Christian Godballe, Jørgen Johansen, Jens Overgaard, Annelise Krogdahl Odense University Hospital, DK. Aim of the study. To evaluate osteopontin expression and its prognostic information in salivary gland cancer. Material.

adina
Download Presentation

Osteopontin expression in salivary gland cancer

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Osteopontin expression in salivary gland cancer Kristine Bjørndal, Christian Godballe, Jørgen Johansen, Jens Overgaard, Annelise Krogdahl Odense University Hospital, DK

  2. Aim of the study To evaluate osteopontin expression and its prognostic information in salivary gland cancer

  3. Material Salivary gland carcinomas treated at Odense University Hospital 1990-2005 48% males and 52% females Clinical data retrieved from the national database DASPYTCA Immunohistochemical investigations performed on surgical specimens Revision

  4. Material 199 patients 3 – records 3 before 1990 5 metastases 10 - tumor 1 – follow-up 3 changed diagnosis 174 patients (OPN + follow-up)

  5. Number of coloured tumor cells 0=none 1=<1/100 2=1/100-1/10 3=1/10-1/3 4=1/3-2/3 5=>2/3 % All salivary gland carcinomas stain. In 87% over 2/3 of the tumor cells are coloured  NO CUT POINT

  6. Colour intensity 0=NONE 1=weak 2=intermediate 3=strong %

  7. Examples

  8. Colour intensities

  9. Kappa beregning i Stata • kap v1 v2, tab • v2 • v1 1 2 3 Total • 1 33 6 0 39 • 2 14 54 11 79 • 3 0 12 45 57 • Total 47 72 56 175 • Expected • Agreement Agreement Kappa Std. Err. Z Prob>Z • 75.43 34.98% 0.6221 0.0539 11.53 0.0000

  10. Histological subtypes

  11. Overlevelsesanalyser Follow-up tid: Tid fra diagnose (dato for den første gang patienten ses på en Øre-Næse-Hals afdeling i forbindelse med aktuelle cancerdiagnose) til censorering, som kunne være: • Død • Sidste follow-up tjek (9. september 2008 Fpas) Hvis patienten var død, blev dødsårsag registreret som en af to: • Død af sin spytkirtelcancer eller af komplikationer til behandling af samme • Død af andre årsager

  12. Datoer • Før selve beregningerne påbegyndes regnes datoer i Excel om til Stata-datoer: • generate double ddate=date(doedcen, "MDY", 2020) • generate double start=date(datoafd, "MDY", 2020) • generate fol=ddate-start • generate folaar=fol/365.25

  13. CS analyser • stset folaar, failure(mors) • stsum • sts graph • sts list • sts graph, ci • stsum, by(ostint) • sts graph, by(ostint)

  14. CS hele materialet

  15. CS hele mat. med CI

  16. CS i.f.t. OPN-status

  17. DSS hele materialet

  18. DSS hele mat med CI

  19. DSS i.f.t. opn-status

  20. Proportional hazards assumption • xi: stcox i.ostint, tvc(ostint) texp(ln(_t)) • P=0,071

  21. Cox-regression • xi: stcox i.ostint • _t Haz. Ratio Std. Err. z P>z [95% Conf. Interval] • _Iostint_2 .6793372 .2538967 -1.03 0.301 .3265545 1.413237 • _Iostint_3 .639291 .2613488 -1.09 0.274 .2868921 1.424553

  22. Conclusion Salivary gland carcinomas express osteopontin Level of osteopontin expression cannot be used as a diagnostic or prognostic marker Osteopontin is a potential target for anti-cancer therapy

More Related